Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
GTX-102 by Ultragenyx Pharmaceutical for Angelman Syndrome: Likelihood of Approval
GTX-102 is under clinical development by Ultragenyx Pharmaceutical and currently in Phase III for Angelman Syndrome. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Ultragenyx Pharmaceutical's GTX-102?
GTX-102 is an antisense oligonucleotide commercialized by Ultragenyx Pharmaceutical, with a leading Phase III program in Angelman Syndrome. According to...
Risk adjusted net present value: What is the current valuation of Ultragenyx Pharmaceutical's GTX-102?
GTX-102 is an antisense oligonucleotide commercialized by Ultragenyx Pharmaceutical, with a leading Phase II program in Angelman Syndrome. According to...